PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine.

Abstract

Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

• Authors: Messoud Ashina, Faisal Mohammad Amin, Pinar Kokturk, Joshua M Cohen, Martijn Konings, Cristina Tassorelli, Leonidas Lyras, Dimos-Dimitrios Mitsikostas
• Journal: Pain management (Pain Manag) Vol. 11 Issue 6 Pg. 647-654 (Nov 2021) ISSN: 1758-1877 [Electronic] England
• PMID: 34105377 (Publication Type: Journal Article, Observational Study)

Chemical References

• Antibodies, Monoclonal
• fremanezumab

Topics

• Adult
• Antibodies, Monoclonal
• Double-Blind Method
• Humans
• Migraine Disorders (drug therapy)
• Observational Studies as Topic
• Prospective Studies
• Treatment Outcome